KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) EBIT (2016 - 2025)

Historic EBIT for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $2.1 billion.

  • Abbott Laboratories' EBIT rose 1065.09% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 billion, marking a year-over-year increase of 1522.26%. This contributed to the annual value of $6.8 billion for FY2024, which is 535.66% up from last year.
  • Abbott Laboratories' EBIT amounted to $2.1 billion in Q3 2025, which was up 1065.09% from $2.1 billion recorded in Q2 2025.
  • Abbott Laboratories' 5-year EBIT high stood at $2.9 billion for Q1 2022, and its period low was $1.3 billion during Q4 2022.
  • Its 5-year average for EBIT is $1.9 billion, with a median of $1.8 billion in 2023.
  • Per our database at Business Quant, Abbott Laboratories' EBIT skyrocketed by 17823.22% in 2021 and then tumbled by 4817.99% in 2023.
  • Quarter analysis of 5 years shows Abbott Laboratories' EBIT stood at $2.4 billion in 2021, then crashed by 45.16% to $1.3 billion in 2022, then skyrocketed by 36.5% to $1.8 billion in 2023, then increased by 7.36% to $1.9 billion in 2024, then rose by 7.64% to $2.1 billion in 2025.
  • Its EBIT was $2.1 billion in Q3 2025, compared to $2.1 billion in Q2 2025 and $1.7 billion in Q1 2025.